These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
160 related articles for article (PubMed ID: 33133773)
1. Predictive Biomarker for Progression Into the Sunset Glow Fundus of Vogt-Koyanagi-Harada Disease, Using Adaptive Binarization of Fundus Photographs. Komuku Y; Ishikawa H; Ide A; Matsuoka T; Fukuyama H; Okadome T; Gomi F Transl Vis Sci Technol; 2020 Oct; 9(11):10. PubMed ID: 33133773 [TBL] [Abstract][Full Text] [Related]
2. Polarization-Sensitive Optical Coherence Tomographic Documentation of Choroidal Melanin Loss in Chronic Vogt-Koyanagi-Harada Disease. Miura M; Makita S; Yasuno Y; Tsukahara R; Usui Y; Rao NA; Ikuno Y; Uematsu S; Agawa T; Iwasaki T; Goto H Invest Ophthalmol Vis Sci; 2017 Sep; 58(11):4467-4476. PubMed ID: 28863408 [TBL] [Abstract][Full Text] [Related]
3. Early post-treatment choroidal thickness to alert sunset glow fundus in patients with Vogt-Koyanagi-Harada disease treated with systemic corticosteroids. Hirooka K; Saito W; Namba K; Mizuuchi K; Iwata D; Hashimoto Y; Ishida S PLoS One; 2017; 12(2):e0172612. PubMed ID: 28241069 [TBL] [Abstract][Full Text] [Related]
4. A clinical grading system based on ultra-wide field retinal imaging for sunset glow fundus in Vogt-Koyanagi-Harada disease. Lee EK; Lee SY; Yu HG Graefes Arch Clin Exp Ophthalmol; 2015 Mar; 253(3):359-68. PubMed ID: 25017008 [TBL] [Abstract][Full Text] [Related]
5. The effect on choroidal changes of the route of systemic corticosteroids in acute Vogt-Koyanagi-Harada disease. Park UC; Cho IH; Lee EK; Yu HG Graefes Arch Clin Exp Ophthalmol; 2017 Jun; 255(6):1203-1211. PubMed ID: 28382438 [TBL] [Abstract][Full Text] [Related]
6. Correlation Between Hyperreflective Foci in the Choroid and Choroidal Discoloration in Vogt-Koyanagi-Harada Disease. Kim YH; Togloom A; Oh J Invest Ophthalmol Vis Sci; 2022 Aug; 63(9):27. PubMed ID: 36006654 [TBL] [Abstract][Full Text] [Related]
7. Sunset glow fundus in Vogt-Koyanagi-Harada disease with or without chronic ocular inflammation. Keino H; Goto H; Usui M Graefes Arch Clin Exp Ophthalmol; 2002 Oct; 240(10):878-82. PubMed ID: 12397437 [TBL] [Abstract][Full Text] [Related]
8. Quantitative evaluation of "sunset glow" fundus in Vogt-Koyanagi-Harada disease. Suzuki S Jpn J Ophthalmol; 1999; 43(4):327-33. PubMed ID: 10482481 [TBL] [Abstract][Full Text] [Related]
9. Evaluation of microvasculature alterations in convalescent Vogt-Koyanagi-Harada disease using optical coherence tomography angiography. Fan S; Lin D; Hu J; Cao J; Wu K; Li Y; Liu R; Dai ML; Bao Z; Wang Y Eye (Lond); 2021 Jul; 35(7):1993-1998. PubMed ID: 33024324 [TBL] [Abstract][Full Text] [Related]
10. Mycophenolate mofetil combined with systemic corticosteroids prevents progression to chronic recurrent inflammation and development of 'sunset glow fundus' in initial-onset acute uveitis associated with Vogt-Koyanagi-Harada disease. Abu El-Asrar AM; Dosari M; Hemachandran S; Gikandi PW; Al-Muammar A Acta Ophthalmol; 2017 Feb; 95(1):85-90. PubMed ID: 27535102 [TBL] [Abstract][Full Text] [Related]
11. Pretreatment ocular blood flow and retinal oxygen metabolism in the acute uveitic phase is associated with final outcome in Vogt-Koyanagi-Harada disease. Abu El-Asrar AM; AlBloushi AF; Alzubaidi A; Gikandi PW; Stefánsson E Acta Ophthalmol; 2024 Sep; 102(6):720-727. PubMed ID: 38470990 [TBL] [Abstract][Full Text] [Related]
14. Predictive factors and adalimumab efficacy in managing chronic recurrence Vogt-Koyanagi-Harada disease. Feng H; Chen W; Yang J; Kong H; Li H; He Y; Wang H BMC Ophthalmol; 2024 Jun; 24(1):238. PubMed ID: 38849758 [TBL] [Abstract][Full Text] [Related]
15. Depigmented atrophic lesions in sunset glow fundi of Vogt-Koyanagi-Harada disease. Inomata H; Rao NA Am J Ophthalmol; 2001 May; 131(5):607-14. PubMed ID: 11336935 [TBL] [Abstract][Full Text] [Related]
16. Adalimumab treatment for chronic recurrent Vogt-Koyanagi-Harada disease with sunset glow fundus: A multicenter study. Takeuchi M; Nakai S; Usui Y; Namba K; Suzuki K; Harada Y; Kusuhara S; Kaburaki T; Tanaka R; Takeuchi M; Mizuki N; Nakai K; Goto H; Herbort CP Saudi J Ophthalmol; 2022; 36(4):380-386. PubMed ID: 36618573 [TBL] [Abstract][Full Text] [Related]
17. Objective evaluation of choroidal melanin loss in patients with Vogt-Koyanagi-Harada disease using polarization-sensitive optical coherence tomography. Miura M; Makita S; Yasuno Y; Azuma S; Mino T; Yamaguchi T; Iwasaki T; Nemoto R; Shimizu H; Goto H Sci Rep; 2022 Mar; 12(1):3526. PubMed ID: 35241784 [TBL] [Abstract][Full Text] [Related]
18. Association between severity of inflammation in CNS and development of sunset glow fundus in Vogt-Koyanagi-Harada disease. Keino H; Goto H; Mori H; Iwasaki T; Usui M Am J Ophthalmol; 2006 Jun; 141(6):1140-1142. PubMed ID: 16765691 [TBL] [Abstract][Full Text] [Related]
19. Prognostic value of pretreatment indocyanine green angiography in the acute uveitic phase of Vogt-Koyanagi-Harada disease. Tobaigy MF; Abouammoh MA; AlBloushi AF; Saifaldein AA; Gikandi P; Almousa AN; Herbort CP; El-Asrar AA Acta Ophthalmol; 2024 Aug; 102(5):e679-e686. PubMed ID: 38131519 [TBL] [Abstract][Full Text] [Related]
20. Acquired myopia in Vogt-Koyanagi-Harada disease. Takahashi H; Takase H; Terada Y; Mochizuki M; Ohno-Matsui K Int Ophthalmol; 2019 Mar; 39(3):521-531. PubMed ID: 29397539 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]